Key clinical point: Celecoxib appeared to be relatively safer compared with nonselective nonsteroidal anti-inflammatory drugs (NSAID) or placebo in patients with rheumatoid arthritis (RA), regardless of dose or duration.
Major finding: Celecoxib was associated with a lower risk for all-cause mortality (risk ratio [RR] 0.81; 95% CI 0.66-0.98) and cardiovascular morality (RR 0.75; 95% CI 0.57-0.99) compared with NSAIDs and a similar risk for all-cause mortality (RR 0.92; 95% CI 0.26-3.27) and cardiovascular morality (RR 3.02; 95% CI 0.36-25.27) compared with placebo.
Study details: Findings are from a meta-analysis of 21 randomized clinical studies that compared cardiovascular safety of celecoxib with NSAIDs or placebo in patients with RA or osteoarthritis.
Disclosures: This study was supported by the National Natural Science Foundation project and others. No competing interests were declared.
Source: Cheng BR et al. PLoS One. 2021;16(12):e0261239 (Dec 21). Doi: 10.1371/journal.pone.0261239.